Choosing upfront and salvage therapy for myeloma in the ASEAN context
|
|
- Mark Webb
- 5 years ago
- Views:
Transcription
1 Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
2 Overall Survival Impact of Novel Agents Up-front mos. Kumar, S et al. Blood 111:2516, 2008.
3 ASEAN s Perspective?? Resources Access to drugs Access to good clinical trials Pharmaceutical representations
4 Evidence-Based Medicine
5 Evidence-Based Medicine
6 Choosing the optimal therapy for myeloma patients Ability to optimize available resources to achieve best outcomes for our patients
7 Questions??? Is risk stratification of myeloma necessary? What is the best induction regimen? Combination or Sequential? Is attaining CR important? Is HDT/ transplant still necessary? What is the best treatment at relapse?
8 Questions??? Is risk stratification of myeloma necessary? What is the best induction regimen? Combination or Sequential? Is attaining CR important? Is HDT/ transplant still necessary? What is the best treatment at relapse?
9 Questions??? Is risk stratification of myeloma necessary? What is the best induction regimen? Combination or Sequential Certainly! Is attaining CR important? Prognostication Is HDT/ transplant still necessary? Research What is the best tx at relapse? Cross trials comparison Individualize treatment- Risk adapted
10 Risk Stratification ISS Stage PC Labelling Index Metaphase Karyotype Interphase FISH GEP B 2 MG Albumin $$$$ $
11
12 Frontline Treatment Bortezomib in del 13 : Jagannath, S et al. Leukemia 21:151, 2007 Bortezomib in t(14q32) : Sagaster, V et al. Leukemia 21:164, Bortezomib in del 13, t(4;14) and/or del 17p : IFM 2005/01 Trial and VISTA Trial 2008
13 Risk Stratification: Overall Survival by ISS SGH (n=218) ISS Median OS(yrs)) I 8.6 II 3.6 III 2.5 p<0.001 Tan D et al. XII th IMW 2009 Abstract # 0286
14 Overall Survival by Metaphase Karyotype SGH (n=213) Ploidy number Median OS(yrs) Normal diploid 8.7 Hyperdiploid 3.8 Non-hyperdiploid Hypodiploid 2.4 Pseudodiploid 2.6 Near-tetraploid not reached Near-tetraploid Normal diploid (51%) Non-hyperdiploid (27%) Hyperdiploid (22%) Pseudodiploid p<0.001 Hypodiploid Tan D et al. XII th IMW 2009 Abstract # 0286 Rajkumar et al. Cytogenetic abnormalities correlate with the plasma cell labelling index. Cancer Genet Cytogenet. 1999;113(1):73-7.
15 Overall survival by Metaphase Karyotyping and Interphase FISH Normal diploid with high-risk FISH t(4;14), t(14;16) & del17p Ploidy number Median OS(yrs) Ploidy Normal status diploid Median OS(yrs) 8.7 Normal Hyperdiploid without Non-hyperdiploid high- risk FISH Hypodiploid 2.4 Hyperdiploid 3.8 Pseudodiploid 2.6 Non-hyperdiploid 2.6 Near-tetraploid not reached Normal diploid with 1.5 high-risk FISH Near-tetraploid Normal diploid (51%) Normal diploid Non-hyperdiploid (27%) Hyperdiploid (22%) Pseudodiploid Hyperdiploid p<0.001 p<0.001 Non-hyperdiploid Hypodiploid
16 Overall Survival by ISS Risk Group and Bortezomib Exposure Bortezomib- Naïve Bortezomib- Exposed ISS Median OS (yrs) High Risk I % II % III % ISS Median OS (yrs) High Risk I % II % III % ISS I ISS II ISS II p<0.001 ISS III p=0.4 ISS III ISS I p=0.04 Tan D et al. XII th IMW 2009 Abstract # 0286
17 Overall Survival by Metaphase Cytogenetics and Bortezomib Exposure Bortezomib- Naïve Bortezomib- Exposed Ploidy number Median OS(yrs) Normal Diploid 8.7 Hyperdiploid 2.9 Non-hyperdiploid 2.2 Ploidy number Median OS(yrs) Normal Diploid not reached Hyperdiploid 4.7 Non-hyperdiploid 2.7 p<0.001 p=0.002 Tan D et al. XII th IMW 2009 Abstract # 0286
18 Subjects without event (%) VISTA Trial: VMP vs MP then V 100 VMP 80 MP->V 60 MP Group N Event VMP MP with bortezomib MP with no bortezomib Time (months) San Miguel J, et al. N Engl J Med. 2008: 359:
19 Risk Stratification for Induction Therapy (SGH) ISS III / Non-hyperdiploidy Clinical trial if available Bortezomib-Combination Bortezomib if reimbursement permits VTD >TD (Cavo et al) TD >VAD (Cavo et al 2005) Bort/Dex >VAD (IFM 2005/01) VMP >MP (VISTA trial) VMPT >VMP weekly (Palumbo et al 09) >Dex (ECOG 2004) MPT >MP (Palumbo et al, Facon et al, Hulin et al) Rd >RD pending approval in frontline use (Rajkumar et al)
20 Questions??? Is risk stratification of myeloma necessary? What is the best induction regimen? Combination or Sequential? Is attaining CR important? Is HDT/ transplant still necessary? What is the best treatment at relapse?
21 MRD Monitoring: What is CR? BM plasma cells <5% M-band Immunofixation Free Light Chains Immunophenotype PCR exposed surface Kappa hidden surface hinge region Previously hidden surface carbohydrate Lambda Intact Immunoglobulin Free Light Chain Bradwell, Serum free light chain assay PR VGPR Stringent CR CR Immunophenotypic CR Molecular CR Tumor Burden $$$$ $
22 Depth of Response Treatment initiation Progression? MR PR VGPR ncr CR scr IP/mCR Time Depth of response is related to TTP
23 Cumulative Proportion Surviving OS by Induction Response 1,0 0,9 0,8 0,7 CR 0,6 0,5 ncr PR 0,4 0,3 0,2 P= 0.01 PD Months from diagnosis Lahuerta et al. JCO. 2008;10:5775 Harousseau et al. J Clin Oncol 2009; 27: 5720
24 Patients without event (%) VMP : CRs Have Superior TTP 100 TTP Group N Event Median CR NA PR <PR CR PR <PR Time (months) CR associated with significantly longer TTP vs. PR (HR 0.45, P=0.004) Significant benefit also seen for CR + PR vs. <PR Harousseau, JL et al ASH Abstract 2778.
25 Attainment of VGPR after induction is an important surrogate of longer survival. Tan D et al. Bone Marrow Transplant Feb15 [epub ]
26 Attainment of VGPR after induction is an important surrogate of longer survival. PFS OS 1-yr landmark Tan D et al. Bone Marrow Transplant Feb 15 [epub]
27 OS of patients achieving VGPR by transplant status HDT/ASCT (n) Median OS (yrs)) Yes (42) 8.1 No (25) not reached HDT/ASCT VAD 57% Thal/Dex or MPT 26% Bort Combi 10% No HDT 7% 57% 30% P=0.76 P=0.76 Tan D et al. Bone Marrow Transplant Feb 15 [epub]
28
29
30 How Long To Treat? Niesvizky et al. Blood 2008;111:11019
31 YES! NO! CR Post-ASCT Important in High-risk MM? Source Chang et al Br J Haem. 2004;25:64 Chang et al Blood :358 Gertz et al Blood.2005;106:2837 Cavo et al. J Clin Oncol. 2006;20;24 Study The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission Source Harousseau et al. J Clin Oncol. 2009;114:3139 Study Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy. t(4;14)(p16.3;q32), and -17p13 Haessler J et al. Clin Cancer Res 2007; 13(23): Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
32 An Abnormal Non-Hyperdiploid Karyotype Predicts for an Adverse Outcome After HDT/ASCT (N=77) PFS OS Ploidy No. PFS (yrs) Diploid 4.0 Hyperdiploid 2.3 Non-hyperdiploid 2.2 Normal Diploid Ploidy No. PFS (yrs) Diploid NR Hyperdiploid 6.3 Non-hyperdiploid 2.8 Normal Diploid Hyperdiploid Non-hyperdiploid P=0.02 Hyperdiploid P<0.001 Non-hyperdiploid Tan D et al. 36 th EBMT Meeting Abstract #896
33 Study Design Primary analysis: post-induction response in VAD (A1+A2) vs. Bort/Dex (B1+B2) Randomization; Stratified by b 2 -microglobulin level (>3 mg/l vs 3 mg/l) and presence of chromosome 13 abnormalities (by FISH) A1 A2 B1 B2 VAD x 4 VAD x 4 Induction Bort/Dex x 4 Bort/Dex x 4 DCEP x 2 Consolidation DCEP x 2 Melphalan 200 mg/m 2 + ASCT Melphalan 200 mg/m 2 + ASCT Transplant 1 Melphalan 200 mg/m 2 + ASCT Second ASCT or RIC allo if <vgpr Melphalan 200 mg/m 2 + ASCT Harrouseau et al. ASH Abstract 353
34 Study Design R E G I S T R A T I O N Thalidomide + Dex T 200 mg po days 1-21 / D 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 q21 x 3 cycles Bortezomib + T + D B 1.3 mg/m 2 days 1, 4, 8, 11 q21 x 3 cycles Double ASCT Melphalan 200 mg/m 2 TD Consolidation VTD Consolidation Cavo et al. ASH abstract #158
35 Conclusions of IFM and GIMEMA Studies A better induction regimen pre-transplant improves the outcomes post-transplant. Earlier use of novel agents improves response rates, which translate to improving long-term outcomes as well
36 Questions??? Is risk stratification of myeloma necessary? What is the best induction regimen? Combination or Sequential? Is attaining CR important? Is HDT/ transplant still necessary? What is the best treatment at relapse?
37 Treatment Options for Relapsed Myeloma No definitive data on optimal sequence Factors to consider : Prior tx and response duration Toxicities from prior tx Organ function Patients preference All pts should be encouraged to paticipate in clin trials Always keep in mind future therapies
38 2009 NCCN Guidelines Repeat primary therapy (if relapse at > 6 mos.) Bortezomib (Category 1) Bortezomib/liposomal doxorubicin (1) Lenalidomide/dex (1) Bendamustine (2B) Bortezomib/dex Lenalidomide Hi dose cyclophosphamide, or Cy-VAD Thalidomide, or thalidomide/dex Dex, or DCEP, or DT-PACE 1 year
39 Survival Impact of Novel Agents at Relapse Relapsed before 1998 Relapsed Relapsed Relapsed Relapsed P< Time (months) Kumar, S et al. Blood 111:2516, 2008.
40 Supportive Care of Myeloma in the Asian Context
41 Myeloma Myths in Asia Incidence of DVT lower in Asians on IMIDs? Asians are more vulnerable to bortezomib induced neuropathy? Why are they only producing 3.5 mgvials??
42 360 pts Retrospective 25 Centres Incidence in Singapore General Hospital: 12/150 (8%)
43 Myeloma Myths in Asia Incidence of DVT lower in Asians on IMIDs? Asians are more vulnerable to bortezomib induced neuropathy? Why are they only producing 3.5 mgvials??
44 Incidence of PN in Bortezomib front-line trials in elderly patients Study VISTA 1 VMP 14% MP 0% PETHEMA/G VMP 15% EM 2 VTP 9% GIMEMA 3 Grade 3/4 PN VMP Biweekly: 14% VMPT Biweekly: 24% Italian study 4 PAD-ASCT(MEL100) 11% Once weekly: 3% Once weekly: 9% Asian Incidence?? 1. San Miguel et al. ASH 2008 (abstract 650) 2. Mateos et al. ASH 2008 (abstract 651) 3. Palumbo et al. ASH 2008 (abstract 652) 4. Palumbo et al. ASH 2008 (abstract 159)
45 Bortezomib dose modification for the management of PN Severity of PN signs/symptoms Grade 1 (paresthesia and/or loss of reflexes without pain or loss of function) Grade 1 with pain or Grade 2 (interfering with function but not with ADL) Grade 2 with pain or Grade 3 (interfering with ADL) Grade 4 (permanent sensory loss interfering with function) Modification of dose and regimen No action Reduce bortezomib to 1.0 mg/m 2 Withhold bortezomib until toxicity resolves then reinitiate at 0.7 mg/m 2 and administer once per week Discontinue bortezomib ADL, activities of daily living
46 Myeloma Myths in Asia Incidence of DCT lower in Asians on IMIDs Asians are more vulnerable to bortezomib induced neuropathy? Why are they only producing 3.5 mgvials??
47 Risk of Hepatitis B Virus (HBV) Reactivation and the Role of Anti-Viral Prophylaxis in Multiple Myeloma Patients with HBV Infection in the Era of Novel Therapies. Hep B reactivation during immune reconstitution post-transplant Role of imids? Emerging incidence of mutant strains Mya et al ASH Abstract #3882
48 Conclusions Is risk stratification of myeloma necessary? Yes! What is the best induction regimen? Earlier use of novel agents improves RR and long-term outcomes Combination outperforms sequencing Is attaining CR important? Yes! Excellent predictors of long-term benefit for myeloma patients in the up-front setting Pushing for a CR pre-transplant appears to be improving the outcome after transplant Is HDT/ transplant still necessary? Yes
49 Prognosis of Myeloma in SE Asia Overall Survival > mos.
50 Thank You
Terapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationOvercoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma
Overcoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma George Somlo M.D. City of Hope Comprehensive Cancer Center The Cause 1 Myeloma: Clinical Features Bone
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationOvercoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma
Overcoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma George Somlo M.D. City of Hope Comprehensive Cancer Center Objectives 1. Provide background and management
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationRefractory M ultiple Multiple M yeloma Myeloma
Refractory Multiple Myeloma A Case Study Case: #1 48-Year-Old Male Presented to the ER with Fatigue and Acute Severe Lower Back Pain Patient assessment: X-ray of lumbar spine: L4 compression fracture,
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationMinimal residual disease. Bruno Paiva University of Navarra, Spain
Minimal residual disease Bruno Paiva University of Navarra, Spain 1st World Congress on Controversies in Multiple Myeloma. Bangkok, Thailand. May 11-13 214 Oprozomib (ONX 912) Phase I/II Autologous bone
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 9: , 2015
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1895-1900, 2015 Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationNew Treatment Paradigms in Transplant-Eligible Myeloma Patients
New Treatment Paradigms in Transplant-Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Turkey, March 1 st 2013 NEW TREATMENT PARADıGM
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationHow to treat a newly diagnosed young patient with multiple myeloma
How to treat a newly diagnosed young patient with multiple myeloma J.F. San Miguel University of Salamanca, Spain Department of Haematology University of Salamanca Cancer Research Centre Disclosures for
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationMultiple myeloma. November 24, 2017 at Vientiane, Laos
Multiple myeloma November 24, 2017 at Vientiane, Laos Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi, Mahidol University, Thailand Multiple myeloma
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationInternational Myeloma Foundation Patient and Family Seminar
International Myeloma Foundation Patient and Family Seminar Vienna, Austria May 6 th, 2006 New Development in Diagnosis & Treatments Brian G.M. Durie, M.D., Chairman International Myeloma Foundation What
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationTherapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 977-982, 2013 Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients CHENGCHENG FU, JUAN WANG, XUE XIN, HUI LIU,
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationOncologist. The. Academia Pharma Intersect: Myelomas. Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective
The Oncologist Academia Pharma Intersect: Myelomas Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective HEINZ LUDWIG, a MERAL BEKSAC, b JOAN BLADÉ, c JAMIE CAVENAGH,
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationKEY WORDS: Multiple myeloma, Autologous transplantation, Induction therapy
Short Course Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma Cristina
More informationReview of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM
Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM Multiple myeloma Response evaluation Kumar Lancet Oncol 2016; 17: e328 46 Cumulative Proportion Surviving
More informationUltra High-Risk Myeloma
UNDERSTANDING AND MANAGING ULTRA HIGH-RISK HEMATOLOGIC MALIGNANCIES Ultra High-Risk Myeloma Hervé Avet-Loiseau 1 1 Laboratoire d Hématologie, Institut de Biologie, Nantes, France Ultra high-risk myeloma
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationmsmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma
msmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma msmart Multiple myeloma is increasingly recognized as more than one disease, characterized by marked cytogenetic,
More informationPlasma cells in bone marrow. Treatment of Multiple Myeloma Novel Approaches. Approach to Progressive MM. Approach to Initial Therapy
Treatment of Multiple Myeloma ovel Approaches Plasma cells in bone marrow Donna E. Reece, M.D. Princess Margaret Hospital Toronto, 21 ctober 25 Adhesion Molecules and Growth Factors in Multiple Myeloma
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationDebate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College /
More informationStudy Objectives: GMMG MM5
Study Objectives: GMMG MM5 1.) Demonstration of non-inferiority of VCD induction therapy compared to PAd induction therapy with respect to response rate (very good partial remission or better; response
More informationAperTO - Archivio Istituzionale Open Access dell'università di Torino
AperTO - Archivio Istituzionale Open Access dell'università di Torino Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More information